In:
Drug Development Research, Wiley, Vol. 75, No. S1 ( 2014-11)
Abstract:
Postmarketing Phase IV Psoriasis is a chronic inflammatory skin disease affecting up to 2.5% of the population, with joint involvement in approximately 30% of patients. Given the role of tumor necrosis factor ( TNF ) in the pathogenesis of psoriasis, anti‐ TNF therapies have been developed; several studies have demonstrated the efficacy of infliximab ( IFX ) as induction and maintenance therapy in the treatment of moderate to severe plaque psoriasis. The development of antinuclear antibodies ( ANA ) in anti‐ TNF ‐treated patients has been frequently reported. The aim of this study was to investigate the incidence of ANA and anti‐double stranded DNA (anti‐ds DNA ) antibodies in psoriatic patients receiving IFX . Incidence of new ANA and anti‐ds‐ DNA was 16.2% and 8.1% respectively. No case of anti‐ TNF induced L upus was observed during the follow‐up.
Type of Medium:
Online Resource
ISSN:
0272-4391
,
1098-2299
DOI:
10.1002/ddr.2014.75.issue-s1
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1500191-X
SSG:
15,3
Permalink